Hospital
Clara Maass Medical Center
Clara Maass Medical Center was paid $156.84M by Medicaid between Jan 2018 and Dec 2024, across 401 billing codes. Its largest line is G0378, Hospital observation service, per hour — 17% of everything it billed.
33Billing provider infoCLARA MAASS MEDICAL CENTER
BELLEVILLE, NJ 07109
BELLEVILLE, NJ 07109
33aNPI1902901333assigned 09/13/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$156.84M
24GClaims2,160,558
24DCodes billed401
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#9 of 93
Median peer was paid$30.60M
This provider vs. median5.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 274,635 | $22.31M | |
| 2019 | 295,579 | $21.47M | |
| 2020 | 208,303 | $15.96M | |
| 2021 | 291,304 | $23.49M | |
| 2022 | 370,336 | $25.23M | |
| 2023 | 408,323 | $25.28M | |
| 2024incomplete | 312,078 | $23.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 17% | 39,630 | 34,423 | $27.22M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 80,068 | 74,756 | $27.19M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 64,131 | 58,778 | $25.73M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 55,773 | 49,288 | $18.54M |
| OP250 | 3.0% | 169,627 | 120,629 | $4.71M | |
| S9480 | Intensive outpatient psychiatric services, per diem | 2.7% | 5,529 | 5,023 | $4.20M |
| 58558 | 2.1% | 1,981 | 1,875 | $3.36M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 14,993 | 14,018 | $3.34M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.9% | 2,591 | 2,375 | $2.91M |
| T2034 | Crisis intervention, waiver; per diem | 1.2% | 2,223 | 2,086 | $1.90M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 3,277 | 3,072 | $1.64M |
| 80053 | Comprehensive metabolic panel | 1.0% | 91,988 | 78,800 | $1.64M |
389 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.0% | 7,305 | $1.64M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.0% | 586 | $1.59M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 28,660 | $1.12M |
| OP710 | <1% | 21,022 | $1.09M | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 12,984 | $984K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 664 | $844K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,019 | $778K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,875 | $681K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,128 | $663K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 4,478 | $659K |
| 97803 | <1% | 3,760 | $659K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 23,708 | $655K |
| 71045 | Radiologic examination, chest; single view | <1% | 17,475 | $654K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 8,911 | $621K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 4,991 | $604K |
| 59425 | <1% | 8,631 | $601K | |
| S9484 | Crisis intervention mental health services, per hour | <1% | 885 | $555K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 37,170 | $543K |
| 95811 | <1% | 162 | $535K | |
| 93017 | <1% | 2,876 | $514K | |
| OP258 | <1% | 68,870 | $475K | |
| OP272 | <1% | 21,265 | $474K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 44,137 | $471K |
| 36415 | Collection of venous blood by venipuncture | <1% | 112,434 | $462K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 33,163 | $451K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,727 | $432K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 39,996 | $410K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 5,112 | $393K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 785 | $384K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,314 | $380K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 10,270 | $375K |
| 76801 | <1% | 3,832 | $356K | |
| 97802 | <1% | 1,360 | $352K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 31,984 | $331K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,686 | $327K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 10,124 | $325K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,152 | $319K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 23,556 | $316K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 92,498 | $315K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 19,121 | $307K |
| OP370 | <1% | 16,573 | $306K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,271 | $257K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,830 | $234K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,184 | $221K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,068 | $215K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 18,502 | $213K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,799 | $212K |
| 97010 | <1% | 10,524 | $199K | |
| 81001 | <1% | 38,707 | $193K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,765 | $183K |
| 73562 | <1% | 4,873 | $181K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,737 | $178K |
| OP278 | <1% | 927 | $177K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,992 | $170K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 29,001 | $166K |
| 73630 | <1% | 4,026 | $155K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,468 | $154K |
| 93458 | <1% | 175 | $154K | |
| 73130 | <1% | 3,541 | $141K | |
| 88342 | <1% | 3,048 | $139K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,936 | $139K |
| 81003 | <1% | 21,117 | $135K | |
| 73030 | <1% | 3,499 | $131K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,908 | $129K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 38 | $122K |
| 93970 | <1% | 1,673 | $121K | |
| 73610 | <1% | 3,911 | $118K | |
| 82962 | <1% | 21,279 | $118K | |
| 81025 | <1% | 15,180 | $113K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,701 | $110K |
| 97014 | <1% | 3,546 | $108K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 4,923 | $105K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 105 | $105K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,701 | $105K |
| 74150 | <1% | 3,141 | $99K | |
| 76813 | <1% | 801 | $98K | |
| 87081 | <1% | 7,844 | $98K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,264 | $97K |
| 59430 | <1% | 1,733 | $96K | |
| 59025 | Fetal non-stress test | <1% | 194 | $91K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 545 | $90K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,140 | $87K |
| 93975 | <1% | 1,084 | $86K | |
| 76770 | <1% | 921 | $86K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,843 | $86K |
| 86900 | <1% | 14,611 | $85K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 2,568 | $83K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,844 | $79K |
| 73110 | <1% | 2,058 | $77K | |
| 87631 | <1% | 2,617 | $76K | |
| 93971 | <1% | 1,995 | $74K | |
| 86850 | <1% | 14,635 | $74K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,168 | $71K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,976 | $70K |
| 58661 | <1% | 98 | $70K | |
| 97162 | <1% | 2,944 | $68K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 810 | $67K |
| 72100 | <1% | 2,222 | $67K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,075 | $66K |
| 87070 | <1% | 3,663 | $65K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,704 | $65K |
| 97161 | <1% | 2,218 | $64K | |
| 84484 | <1% | 22,082 | $60K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,089 | $60K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,855 | $59K |
| 76830 | Ultrasound, transvaginal | <1% | 497 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,038 | $56K |
| 74246 | <1% | 402 | $55K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,471 | $51K |
| 74018 | <1% | 1,692 | $50K | |
| 70486 | <1% | 1,129 | $49K | |
| 87430 | <1% | 11,490 | $48K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 630 | $47K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 13,172 | $45K |
| 84703 | <1% | 27,693 | $43K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 31,958 | $43K |
| 47562 | <1% | 28 | $41K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 128 | $41K |
| 96376 | <1% | 6,827 | $40K | |
| 76642 | <1% | 374 | $38K | |
| 43775 | <1% | 12 | $38K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,257 | $38K |
| 85610 | <1% | 19,791 | $38K | |
| 87040 | <1% | 4,064 | $37K | |
| 77080 | <1% | 488 | $37K | |
| 80305 | <1% | 6,545 | $37K | |
| 73080 | <1% | 1,070 | $37K | |
| 83880 | <1% | 5,385 | $36K | |
| 86901 | <1% | 14,639 | $36K | |
| A9270 | Non-covered item or service | <1% | 20,273 | $34K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,085 | $33K |
| 72110 | <1% | 513 | $32K | |
| 83690 | <1% | 29,702 | $32K | |
| 72131 | <1% | 619 | $32K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,779 | $32K |
| 85730 | <1% | 18,276 | $31K | |
| 84702 | <1% | 7,705 | $31K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,641 | $31K |
| 29515 | <1% | 1,373 | $31K | |
| 87400 | <1% | 4,839 | $30K | |
| 71101 | <1% | 684 | $29K | |
| 73590 | <1% | 949 | $29K | |
| C1781 | Mesh (implantable) | <1% | 54 | $29K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 940 | $28K |
| 76641 | <1% | 191 | $26K | |
| 29581 | <1% | 477 | $26K | |
| 76870 | <1% | 341 | $26K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 439 | $25K |
| 82542 | <1% | 1,819 | $25K | |
| 29125 | <1% | 966 | $25K | |
| 88142 | <1% | 772 | $25K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,622 | $24K |
| 67113 | <1% | 30 | $24K | |
| 93798 | <1% | 124 | $24K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,245 | $24K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 531 | $23K |
| 88304 | <1% | 3,407 | $23K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 2,175 | $23K |
| 12001 | <1% | 1,003 | $23K | |
| 10060 | <1% | 491 | $23K | |
| J2704 | Injection, propofol, 10 mg | <1% | 13,355 | $22K |
| 77065 | Tomosynthesis, mammo | <1% | 161 | $22K |
| 80061 | Lipid panel | <1% | 2,785 | $21K |
| 12011 | <1% | 825 | $21K | |
| 85027 | <1% | 8,537 | $21K | |
| 73502 | <1% | 1,369 | $21K | |
| 77336 | <1% | 202 | $20K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,878 | $20K |
| 86592 | <1% | 2,564 | $20K | |
| 71250 | <1% | 253 | $19K | |
| 95806 | <1% | 31 | $19K | |
| 95800 | <1% | 25 | $19K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,038 | $18K |
| 72040 | <1% | 467 | $17K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 214 | $17K |
| 90715 | <1% | 3,174 | $16K | |
| 87186 | <1% | 1,956 | $15K | |
| 96367 | <1% | 478 | $15K | |
| 70496 | <1% | 149 | $15K | |
| 11045 | <1% | 125 | $15K | |
| 73140 | <1% | 484 | $15K | |
| 87147 | <1% | 1,683 | $14K | |
| 87340 | <1% | 1,963 | $14K | |
| 88307 | <1% | 1,546 | $13K | |
| V2632 | Posterior chamber intraocular lens | <1% | 341 | $13K |
| 87205 | <1% | 1,384 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,742 | $13K |
| 73090 | <1% | 333 | $13K | |
| C1769 | Guide wire | <1% | 1,395 | $12K |
| 83735 | <1% | 6,202 | $12K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 25,318 | $12K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 270 | $12K |
| 95816 | <1% | 43 | $12K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,136 | $12K |
| 70498 | <1% | 127 | $12K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 142 | $11K |
| 87077 | <1% | 1,651 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,272 | $11K |
| 82950 | <1% | 557 | $10K | |
| 88341 | <1% | 446 | $10K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,697 | $9K |
| 87088 | <1% | 3,758 | $9K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,041 | $9K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 125 | $9K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,011 | $9K |
| 97124 | <1% | 570 | $8K | |
| OP270 | <1% | 4,414 | $8K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 135 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,335 | $8K |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 59 | $8K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 43 | $7K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,595 | $7K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,105 | $7K |
| 74241 | <1% | 43 | $7K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,633 | $7K |
| 58662 | <1% | 12 | $7K | |
| 83605 | <1% | 1,770 | $7K | |
| 86787 | <1% | 538 | $7K | |
| 72082 | <1% | 85 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,523 | $7K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 888 | $7K |
| 85007 | <1% | 4,999 | $6K | |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | <1% | 48 | $6K |
| 83021 | <1% | 329 | $6K | |
| 87807 | <1% | 427 | $6K | |
| 97166 | <1% | 159 | $6K | |
| 86765 | <1% | 619 | $6K | |
| 87486 | <1% | 357 | $5K | |
| 86703 | <1% | 424 | $5K | |
| S9451 | Exercise classes, non-physician provider, per session | <1% | 57 | $5K |
| 15853 | <1% | 347 | $5K | |
| 88312 | <1% | 546 | $5K | |
| 87075 | <1% | 254 | $4K | |
| 77066 | Tomosynthesis, mammo | <1% | 26 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 359 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 492 | $4K |
| 36430 | <1% | 140 | $4K | |
| 93226 | <1% | 12 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 8,022 | $4K |
| 72050 | <1% | 52 | $4K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 151 | $4K |
| 82248 | <1% | 113 | $4K | |
| 72070 | <1% | 165 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,721 | $3K |
| 86480 | <1% | 94 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,443 | $3K |
| 84100 | <1% | 1,738 | $3K | |
| 87641 | <1% | 250 | $3K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 530 | $3K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 513 | $3K |
| 43235 | <1% | 12 | $3K | |
| 30520 | <1% | 12 | $3K | |
| 84550 | <1% | 1,297 | $3K | |
| 74420 | <1% | 175 | $3K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 122 | $3K |
| 76536 | <1% | 30 | $3K | |
| 93225 | <1% | 12 | $3K | |
| 81002 | <1% | 1,104 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 845 | $3K |
| 87581 | <1% | 357 | $3K | |
| 85378 | <1% | 3,244 | $3K | |
| 83615 | <1% | 879 | $3K | |
| 84439 | <1% | 433 | $2K | |
| 29505 | <1% | 49 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 250 | $2K |
| 86308 | <1% | 347 | $2K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 82 | $2K |
| 12002 | <1% | 108 | $2K | |
| 29130 | <1% | 96 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 137 | $2K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 401 | $2K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 423 | $2K |
| 97116 | <1% | 358 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 89 | $2K |
| 82805 | <1% | 88 | $2K | |
| 82728 | <1% | 157 | $2K | |
| 86780 | <1% | 207 | $2K | |
| OP637 | <1% | 2,124 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,547 | $1K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 200 | $1K |
| 85379 | <1% | 536 | $1K | |
| C1765 | Adhesion barrier | <1% | 20 | $1K |
| 0001A | <1% | 51 | $1K | |
| 82010 | <1% | 644 | $1K | |
| 82607 | <1% | 95 | $1K | |
| 82803 | <1% | 99 | $1K | |
| J1335 | Injection, ertapenem sodium, 500 mg | <1% | 134 | $1K |
| 0002A | <1% | 29 | $1K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 23 | $1K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 63 | $1K |
| 88302 | <1% | 271 | $1K | |
| 83540 | <1% | 284 | $1K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 214 | $988.91 |
| 86140 | <1% | 969 | $987.97 | |
| 82746 | <1% | 70 | $880.88 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,893 | $879.51 |
| 86762 | <1% | 418 | $745.39 | |
| 80179 | <1% | 354 | $732.43 | |
| 85651 | <1% | 938 | $731.28 | |
| 97164 | <1% | 15 | $727.00 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,872 | $649.35 |
| 82951 | <1% | 109 | $630.03 | |
| 82550 | <1% | 405 | $604.23 | |
| 85055 | <1% | 68 | $604.16 | |
| 83550 | <1% | 209 | $564.51 | |
| 86920 | <1% | 104 | $562.51 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 38 | $561.44 |
| 82247 | <1% | 195 | $531.44 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 419 | $526.90 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 748 | $524.21 |
| 83970 | <1% | 41 | $510.83 | |
| 73070 | <1% | 12 | $481.44 | |
| 93880 | <1% | 13 | $466.75 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 490 | $462.91 |
| 82570 | <1% | 403 | $454.89 | |
| 88300 | <1% | 202 | $448.46 | |
| 84156 | <1% | 358 | $408.06 | |
| 90686 | <1% | 55 | $381.54 | |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | <1% | 19 | $367.50 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 369 | $360.66 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 607 | $357.36 |
| 80320 | <1% | 69 | $349.03 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 166 | $343.81 |
| 0031A | <1% | 24 | $289.38 | |
| 83020 | <1% | 56 | $286.73 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 976 | $259.37 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 216 | $243.58 |
| 74181 | <1% | 12 | $242.40 | |
| 80143 | <1% | 42 | $235.48 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 169 | $214.69 |
| 87493 | <1% | 16 | $192.46 | |
| 90674 | <1% | 47 | $181.40 | |
| 84075 | <1% | 128 | $174.33 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,159 | $172.70 |
| 94760 | <1% | 81 | $171.20 | |
| 88311 | <1% | 169 | $165.72 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 239 | $156.00 |
| 85652 | <1% | 216 | $151.08 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 126 | $136.95 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 252 | $133.90 |
| 84450 | <1% | 128 | $132.72 | |
| 84145 | <1% | 17 | $115.96 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 412 | $110.47 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 286 | $104.53 |
| 82040 | <1% | 128 | $97.95 | |
| C1758 | Catheter, ureteral | <1% | 79 | $93.38 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 190 | $92.34 |
| 84155 | <1% | 127 | $85.05 | |
| 80055 | <1% | 14 | $75.90 | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 67 | $63.37 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 109 | $59.95 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 272 | $58.93 |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $55.68 |
| 82043 | <1% | 13 | $52.84 | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 277 | $47.21 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 107 | $37.10 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 49 | $35.98 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 34 | $35.54 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 140 | $32.83 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 99 | $31.06 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 59 | $30.80 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 268 | $26.88 |
| 80329 | <1% | 15 | $25.74 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 120 | $23.76 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 123 | $23.00 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 85 | $21.13 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 48 | $17.44 |
| OP255 | <1% | 27 | $16.61 | |
| 82150 | <1% | 12 | $14.78 | |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | <1% | 74 | $14.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 38 | $12.25 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 48 | $12.00 |
| 85008 | <1% | 220 | $12.00 | |
| 84132 | <1% | 74 | $9.19 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 12 | $6.47 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 277 | $0.77 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 18 | $0.38 |
| 94669 | 0% | 19 | $0.00 | |
| 91300 | 0% | 84 | $0.00 | |
| 87899 | 0% | 12 | $0.00 | |
| 87045 | 0% | 12 | $0.00 | |
| 99242 | 0% | 44 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 16 | $0.00 |
| 87427 | 0% | 12 | $0.00 | |
| 99241 | 0% | 17 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 15 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 28 | $0.00 |
| 87046 | 0% | 12 | $0.00 | |
| 81015 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBURKE, THOMAS (PRESIDENT/CEO)
Parent organizationRWJ BARNABAS HEALTH INC
| Provider | Location | Paid |
|---|---|---|
| Ophthalmic Consultants of Long Island | Rockville Centre, NY | $7.83M |
| Burke Dermatology, PA | Newark, DE | $2.38M |
| Neurotech, Na INC. | Manassas, VA | $1.33M |
| Lehigh Valley Eye Center, P.C. | Allentown, PA | $957K |
| Ophthalmic Consultants of Long Island | Stony Brook, NY | $193K |
| Boston Orthopaedic and Spine LLC | Brighton, MA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.